Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed
​Astellas Pharma sees strong revenue and profit growth in FY26, driven by strategic brands and cost optimization. This momentum is expected to...
198 Views
Leakage Report - 5/8/17 - Crazy Volume on First Day Back from Golden Week....
48 out of the approx. 350 names to announce earnings in the next 3 days moved on more than 2 standard deviations of volume. All but one, Otsuka...
532 Views
The Week That Was in NorthAsia@Smartkarma - Jelly Drinks, Dental Implants, & Tires
This is the inaugural report of "The Week That Was in North Asia@Smartkarma. This is a collaborative report among Travis Lundy, Mio Kato, CFA,...
446 Views
Sumitomo Pharma (4506 JP): Placement Is In Line With “Boost 2028” Plan, R&D in Focus
Sumitomo Pharma announced the placement price to be ÂĄ1990 per share. Net proceeds of ÂĄ111.6B yen is expected to be used for R&D in oncology (~...
270 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
643 Views